KUALA LUMPUR, 10 July 2021 – ENVIRO Group Asia has recently launched a WeCARE, a Business For Good (BFG) programme aimed at reaching out to the local communities through its online platforms, and partnership with Non-profit Organisations. The programme started in early July to echo the #kitajagakita movement, and the group is currently in talk and strategising reach-out plans with several organisations.

The Group is set to contribute hygiene kits, hand sanitisers and masks to the needy, and most importantly, lending its 16^th years expertise in the field of indoor hygiene and solutions to organisations and homes, with indoor air quality, testing and disinfection services to keep the community safe.

We can honestly say that we’ve never experienced an event with such a drastic impact on how we live and work as the COVID-19 pandemic. Now more than ever, we must do the right things and be prepared to take steps beyond what we’re typically required to do.

As an experienced indoor air quality hygiene expert, Enviro Group is constantly researching and advancing through our technologies and the solutions provided. In times like this we find ourselves being equipped with the right knowledge and solutions to support others. There is no reason not to step up and serve the community,” says Mr. Nitesh Malani, Group CEO of Enviro Group Asia.

The Group welcomes any local community that requires support to contact its toll free hotline 1800-88-7900 for further discussion.

About Enviro Group Asia

Enviro Group Asia is an integrated indoor air engineering solutions expert with more than 16 years experience in indoor air quality testing and solutions, building remediation, decontamination, disinfection, facilities management, and disaster restoration management solutions across a variety of industries. The Group holds the exclusive distribution for HealthWay, a US-based air purification system, in Malaysia. The Group owns Enviroverks (M) Sdn Bhd, Enviro I.F.M. Sdn Bhd, and Red Carpet Technologies (M) Sdn Bhd.

More information about Enviro Group Asia can be found here:

Website: www.envirogroup.asia

Official Email: support@envirogroup.asia

Official Toll free: 1800-88-7900

Facebook: https://www.facebook.com/envirogroupasia

Instagram: @envirogroupasia

For Media Enquiries, please contact:

Name: Ms. Rachel Khiew

Tel: +6 012 321 9790

Email: rachelkhiew@enviroverks.com.my

Related Articles:

Global COVID-19 Vaccine Efforts

Covid-19 Vaccinations for Malaysia

While the rapid development of vaccines against COVID‑19 is an extraordinary achievement, successfully vaccinating the global population presents many challenges, from production to distribution, deployment, and importantly, acceptance. Trust in the vaccines is vital, and is critically dependant on the ability of governments to communicate the benefits of vaccination, and to deliver the vaccines safely and effectively. This brief addresses the role of governments in promoting confidence in the effectiveness and safety through effective communication, as well as trust in their ability to procure and distribute them efficiently and equitably. While only a small minority of the population holds strong anti-vaccination views, hesitancy about COVID‑19 vaccination is evident in many countries. Recognising that vaccination campaigns of the magnitude needed are unprecedented, government actions to garner trust will be essential to their success, and to the emergence of more resilient societies after the crisis.

 

View this post on Instagram

 

A post shared by ENVIRO Group (@envirogroupasia)

While the development of COVID‑19 vaccines has been an extraordinary success, vaccinating most of the global population is an enormous challenge, one for which gaining – and maintaining – public trust in COVID‑19 vaccines and vaccination will be as essential as the effectiveness of the vaccines themselves. Moreover, the experience with COVID‑19 will likely shape confidence in other vaccines making it even more important to build confidence at this time.

Trust in vaccination, and in the ability of governments to communicate, and to successfully deliver a vaccination programme, is critically dependent on:

• The extent to which the government can instil and maintain public confidence in the effectiveness and safety of the vaccines;
• The competence and reliability of the institutions that deliver them;
• The principles and processes that guide government decisions and actions in vaccine procurement, distribution, prioritisation, and administration;
• The capacity and effectiveness of regulatory agencies in handling issues and communicating consistently as events arise, while retaining public confidence in their review processes; and
• The effectiveness of the public engagement and communications that accompany these.

Given the speed at which COVID‑19 vaccine development has taken place it is important for governments to emphasise that no developmental or regulatory corners were cut in the process, as:

• Development was facilitated by extensive prior research, unprecedented levels of international collaboration among researchers, and massive public investment in R&D and manufacturing capacity; and
• Approval processes were accelerated, in part through procedures that allow the acceptance of more preliminary evidence in circumstances of public emergency; and with COVID‑19 products accorded the highest priority by regulators.

Successful vaccination campaigns also require governments to partner and support community organisations to conduct extensive and well-managed community engagement. A thorough understanding is needed of different populations’ specific concerns, prior experiences both with vaccination and the health system in general, religious and/or political affiliations, and socio-economic status. It is also important to ensure that government actions are open to public scrutiny, and that public institutions engage with the population, by:

• Proactively releasing timely information on vaccination strategies, modalities and accomplishments in disaggregated, user-friendly and open source formats;
• Enhancing transparent and coherent public communication to address misinformation and the “infodemic”; and
• Engaging the public when developing vaccination strategies, and in the form and content of key communications.

Finally, fairness is a hallmark of human behaviour that underpins social cohesion and trust. Governments must therefore manage public expectations and explain why it is fair that particular population groups within a country are prioritised for vaccination.

Related Articles:

Global COVID-19 Vaccine Efforts

Covid-19 Vaccinations for Malaysia

A year into the pandemic of the COVID-19 coronavirus disease, the global effort to develop and distribute an effective vaccine produced several promising options. The accelerated development of multiple vaccines is unprecedented; the process typically takes eight to fifteen years.

Now, the immunization of a critical mass of the world’s population—which is crucial for getting the pandemic under control—is up against a new set of challenges, including dangerous new strains of the virus, global competition over a limited supply of doses, and public hesitation about the vaccines.

 

View this post on Instagram

 

A post shared by ENVIRO Group (@envirogroupasia)

How does a vaccine work?

Traditionally, vaccines are dead or weakened virus molecules—known as antigens—that trigger defensive white blood cells in the immune system to create antibodies that bind to the virus and neutralize it.

There are four main types of conventional vaccines:

• Live vaccines use a weakened form of the virus to prompt the creation of antibodies;
• Inactivated vaccines use a dead version of the virus;
• Toxoid vaccines use toxins made by the virus to produce immunity to the part of the virus that causes disease; and
• Subunit, recombinant, polysaccharide, and conjugate vaccines use proteins or other pieces of the virus.

There are also several types of vaccines that use the virus’s genetic material—DNA or RNA—to prompt the body to create antibodies. More than a dozen of the COVID-19 vaccine candidates that have gone to clinical trials are genetic-based, including those by U.S. pharmaceutical giant Pfizer and partnering German firm BioNTech and by U.S.-based Moderna. No vaccine of this kind had ever been approved for commercial use in humans before the COVID-19 pandemic. Additionally, some COVID-19 vaccines rely on viral vectors, or modified versions of a different virus, to prompt an immune response. Several approved COVID-19 vaccines use viral vectors.

When most of a population has been vaccinated and is immune to a particular disease, even those who are not immune are considered protected because the likelihood of an outbreak is small. This is known as herd immunity. Chicken pox, measles, mumps, and polio are all examples of diseases for which the United States has achieved herd immunity due to vaccines. Scientists are divided about how much of a population must have COVID-19 antibodies to prevent new outbreaks, with estimates ranging from less than half to over 80 percent.

Who is involved in vaccine development?

Vaccines are frequently collaborative efforts across sectors of society, with private pharmaceutical firms teaming up with public health agencies or university labs. Here are snapshots of some of the major players in the COVID-19 vaccine field.

Governments. Public health agencies have played critical roles in supplying funds to develop COVID-19 vaccines.

International institutions. The World Health Organization (WHO) and other multilateral institutions such as the World Bank are focused on financing and manufacturing COVID-19 vaccines for global use, in particular to ensure fair allocation among all countries. 

Private sector. The pharmaceutical industry has been driving much of the push. Companies ranging from biotech start-ups to giants such as U.S.-based Johnson & Johnson shifted their research and development efforts to focus on COVID-19.

Research institutions and non-profits. Many of the COVID-19 vaccine candidates have involved a university or college assisting in preclinical research or clinical trials.

How are COVID-19 treatments helping?

Dozens of treatments—which would not prevent someone from being infected with COVID-19 but could help reduce the severity and duration of illness—have been developed or repurposed. Among them is the antiviral drug Remdesivir, which was developed by U.S.-based Gilead Sciences and approved by the FDA. An NIH-sponsored trial of Remdesivir that involved dozens of sites in the United States, Europe, and Asia showed faster rates of recovery from the virus. Some health experts are also optimistic about the use of dexamethasone, a common steroid, which was found to reduce the risk of death in severely ill COVID-19 patients in the UK. The FDA has authorized emergency use of convalescent plasma, or blood plasma of previously infected people who have created COVID-19 antibodies. Though plasma donations have already been used in tens of thousands of patients, research is ongoing to determine the treatment’s effectiveness.

 

View this post on Instagram

 

A post shared by ENVIRO Group (@envirogroupasia)

Can vaccines end the pandemic?

Even with about a dozen vaccines approved for emergency use, there remains the tremendous challenge of making enough of them for the world’s population.

Meanwhile, several new strains of the coronavirus are raising concerns among scientists and health officials about increased transmission, waning immunity in people already infected with COVID-19, and reduced effectiveness of vaccines that have already been developed. Pfizer, BioNTech, and Moderna are already developing booster shots to increase protection against the new strains. Ahead of U.S. approval for its vaccine, Johnson & Johnson reported that its shot provided higher protection against these strains in clinical studies than initially thought.

Related Articles:

Covid-19 Vaccinations for Malaysia

COVID-19 Propels Indoor Air Quality Solutions as Top Concerns for Businesses to ReLaunch to the “New Normal”

● Singing of MOU on 8th April 2021 between the Head of both companies and website
is launched on the same day
● Special offerings on both companies’ products and services for public and business
sectors, for quicker one-stop solutions.

 

View this post on Instagram

 

A post shared by ENVIRO Group (@envirogroupasia)

Kuala Lumpur, 8 April 2021 – Malaysia premier healthcare provider BP Healthcare and indoor
environmental technologies and engineering solutions provider Enviro Group has
established a partnership in creating stronger health and hygiene solutions for Malaysians.
The signing of the Memorandum of Understanding took place at BP Healthcare office in
Medan Tuanku, and was executed by Ms. Kelly Chung, COO of Doctor2U, BP Healthcare and
Mr. Ahmad Fuad Che Mi, Group General Manager of Enviro Group.

“As a healthcare solutions provider, BP Healthcare is constantly evolving to be at the forefront
of healthcare. We are always looking for the right partner in delivering more values and
coverage to our customers. Today, we are glad to welcome Enviro Group as our partner. With
more than a decade of experience in end-to-end disinfection services and in-door
environmental solutions, we are sure that Enviro Group is able to meet the needs of the
consumer and B2C market,” as mentioned by Ms. Kelly Chung.

BP Healthcare has been at the forefront of Covid-19 screening through heavy investments
and establishing a series of partnerships with different industries to provide more
comprehensive solutions to both public and businesses.

“Meaningful collaborations are important for the benefits of our community, with a partnership
with BP Healthcare, we are able to provide more businesses and the public with much needed
top-to-toe health and indoor hygiene solutions. We believe in protecting people and
assets by providing a cleaner and better indoor environment. Our wish is that Malaysians
continue to uphold the hygiene protocols and not take things for granted,” said Mr. Nitesh
Malani.

Enviro Group specialises in integrated indoor environmental technologies research and
development, providing a full range of services from consultation, in-door air quality monitoring
and cleaning, disinfection and sanitisation, and technical training.
Public and businesses are offered a special discount on the services provided by both
companies via the BP Healthcare website.
The signing ceremony was witnessed by Mr. Gavry Beh, Vice President of BP Healthcare
Group, and Mr. Nitesh Malani, Group CEO of Enviro Group.

 

View this post on Instagram

 

A post shared by ENVIRO Group (@envirogroupasia)

Home is Where the heart is.

HealthWay Air Purifiers are promoted on The Star Special, Sunday 23 May 2021 HOME & LIVING. In this article, we have seen an easy way to reduce the risk of airborne transmission of covid-19.

And as it illustrated, we want to make your home a snug and cosy place to unwind with friends and family. You and your loved ones are deserved to enjoy cleaner and healthier air.

KUALA LUMPUR, May 18 (Bernama) — Malaysia’s leading integrated indoor environmental specialist, ENVIRO Group Asia has successfully done surface sanitisation and decontamination programs covering more than 7,000,000 sqft of both commercial and residential building spaces in efforts to contain the spread of the Covid-19 outbreak in the country. Indoor Air Quality of buildings is at greater risk after more than 60 days of MCO and it’s a must check for businesses to ReLaunch says Nitesh Malani; Group Chief Executive if ENVIRO Group Asia.

“There is much to be learnt still about the current virus outbreak and current evidence suggests that cleaning of surfaces followed by disinfection is the best practice measure for the prevention and spread of Covid-19 and other viral respiratory illnesses in a community setting,” says Nitesh Malani.

Rapid Disinfection Solution or “RDS” incorporates ENVIRO Clean surface disinfectant & ENVIRO Protect a revolutionary surface coating works by “denaturing” the virus’ proteins – effectively twisting them out of shape – and attacking its protective layer of fat. The colourless and odourless substance is applied on surfaces using patented electrostatic technology that bonds its compound both pourous and non-pourous surfaces. It is advisable to be reapplied every three to four months. Positively charged surfaces making viruses and microorganism unviable on applied surface. ENVIRO Protect is applied on high touch point surfaces such as ATM’s, Touch screens, door handles, lift buttons and with high traffic.

This provides a safer surface environment and peace of mind. RDS is a must for Healthcare Facilities, Public transportation, Office Buildings, Schools, Hotels, Shopping Malls and other high traffic areas to prevent the spread of Covid-19.   The technology behind so-called self-disinfecting coatings has been around for almost a decade, and has previously been used in hospitals to fight against the spread of infection, including against antibiotic-resistant bacteria.

In quickly responding to the crisis at hand and the escalating requests for surface cleaning works, Enviro Group introduced the Rapid Disinfection Service (RDS) which employs a combination of its ENVIRO Clean Surface disinfectant containing a broad spectrum of virucidal disinfectants and ENVIRO Protect Surface Protector a patented surface application which offers protection up to 90 days and more on treated surfaces.

“The surface protector that is used contains revolutionary anti-microbial agents which is developed in the US designed to destroy bacteria, germs and viruses, including Staphylococcus (MRSA), C-diff and Influenza-A Virus (including H1N1 & SARS) by forming an anti-microbial shield on the treated surfaces. This unique product is EPA registered as non-toxic, non- hazardous and USDA accepted for protective surface,” adds Nitesh.

ENVIRO Group Asia takes pride in working alongside the Ministry of Health Malaysia’s infection prevention and control protocols and measures while working under stringent global disinfection and sterilisation guidelines.  Government agencies, Multinationals and SME’s are among the many that has commenced upping the efforts in hygiene protocols and disinfecting their premises.

FOR MORE INFORMATION, PLEASE CONTACT:
Name: Ms. Lyly Sharin
Tel: +6012 492 0079

Name: Mr Herain
Tel: +6012 201 4804 | +603 2287 0079

Source: BERNAMA

KUALA LUMPUR, March 16 (Bernama) — Malaysia’s leading integrated indoor environmental specialist, ENVIRO Group Asia has successfully done surface sanitisation and decontamination programs covering more than 5,000,000sqft of both commercial and residential building space in efforts to contain the spread of the Covid-19 outbreak in the country.

“There is much to be learnt still about the current virus outbreak and current evidence suggests that cleaning of surfaces followed by disinfection is the best practice measure for the prevention and spread of Covid-19 and other viral respiratory illnesses in a community setting,” says Nitesh Malani, Group CEO of ENVIRO Group Asia.

In quickly responding to the crisis at hand and the escalating requests for surface cleaning works, Enviro Group introduced the Rapid Disinfection Service (RDS) which employs a combination of its ENVIRO Clean Surface disinfectant containing a broad spectrum of virucidal disinfectants and ENVIRO Protect Surface Protector using BioProtect 500 and patented surface disinfectant which offers protection up to 90 days on treated surfaces.

“The surface protector that is used contains revolutionary anti-microbial agents which is developed in the US designed to destroy bacteria, germs and viruses, including Staphylococcus (MRSA), C-diff and Influenza-A Virus (including H1N1 & SARS) by forming an anti-microbial shield on the treated surfaces. This unique product is EPA registered as non-toxic, non- hazardous and USDA accepted for protective surface,” adds Nitesh.

ENVIRO Group Asia takes pride in working alongside the Ministry of Health Malaysia’s infection prevention and control protocols and measures while working under stringent global disinfection and sterilization guidelines.  Government agencies, Multinationals and SME’s  are among the many that has commenced upping the efforts in hygiene protocols and disinfecting their premises.

FOR MORE INFORMATION, PLEASE CONTACT:
Name: Ms. Lyly Sharin
Tel: +6012 – 492 0079

Name: Mr Herain
Tel:  +6012 – 201 4804 / +603 – 2287 0079

Source: BERNAMA

ENVIROVERKS Malaysia, the leading service provider of Indoor Environmental Quality (IEQ) management in the country launched the Enviro InteliAQ System today which saw the group entering into a collaborative partnership with Alila Bangsar Kuala Lumpur. The collaboration will see the highest guest floor of Alila Bangsar’s studios and suite being upgraded to the Enviro Allergy Friendly rooms.

“This first-in-the-market collaboration will be a game changer for the hospitality industry here in Malaysia as we help Alila Bangsar to assure that guests and staff are exposed to fewer pollutants and contaminations overall,” says Nitesh Malani, Group CEO of ENVIROVERKS Malaysia.

The Enviro InteliAQ System powered by uHoo features a remarkable engineering of nine air quality sensors packed in a tiny device the size of a coffee mug. It is powered by a high-performance ARM-based processor that helps building or facility managers measure and manage indoor air quality.

The ENVIRO Allergy Friendly Rooms provides guest with luxurious comfort and protects against outdoor contaminants that happens during hotel room conversions. These allergy friendly rooms will see smart sensors installed to provide real time data analytics which will then be converted into actionable remedies for guests and the building occupants comfort.

“Alila Bangsar Kuala Lumpur is excited to collaborate with Enviroverks and to be the first hotel in Malaysia to provide an allergy friendly guestroom floor. Alila Bangsar is Alila Hotels & Resort’s first hotel in Malaysia and we are proud to have upgraded all guestrooms on level 40 including the 252 sqm Alila Suite,” says Kamal Munasinghe, General Manager of Alila Bangsar Kuala Lumpur.

Sick Building Syndrome (SBS) or Building Related Illness (BRI) has been a cause of concern for most building occupants who fall ill due to poor indoor air quality. “Recent innovations in low-cost air pollution sensors has enabled a new generation of air quality monitoring devices that provides actionable high-resolution data at a fraction of the cost of traditional monitoring systems,” says Dustin J. Onghanseng, co-founder and CEO of uHoo International.

“Air quality used to be something that people rely on manual method for information on. Today, technology with IoT has improved dramatically that sensors are now shrunk so small that you can monitor the quality of air you breathe in your homes or offices. This is important because we spend more than 80% of our time indoors.”

Enviro Group Asia has also entered into a collaborative distribution and research and development agreement with uHoo International which will see the group expanding its regional footprint in the building sciences and environmental engineering sector. Malaysia is the first country to have launch InteliAQ before this is introduced in other regional markets.

The group’s partnership with uHoo International will also give rise to new indoor air quality sensing technologies that will pave the way to a wealth of data that can be used to better manage indoor air quality. The onset of Internet of Things ‘IoT’ will also see potential industries such as healthcare facilities, education institutions and retail spaces being more committed to the well-being of their building occupants by adopting cost-effective technologies and remedial services.

Source: BusinessCircleKL

The rising number of chronic diseases linked to poor indoor air quality has brought to light the urgency for a better understanding in addressing the challenge.

Sick Building Syndrome (SBS) or Building Related Illness (BRI) has been a cause of concern for most building occupants but with recent innovations in low-cost air pollution sensors, it has enabled a new generation of air quality monitoring devices that provides actionable high-resolution data at a fraction of the cost of traditional monitoring systems.

Enviro Group Asia, through its subsidiary ENVIROVERKS Malaysia is proud to launch the first in the market ENVIRO INTELiAQ – a revolutionary air quality monitoring system that aims to innovate how air quality in measured and managed.

The media launch will be followed by a panel discussion spearheaded by ENVIROVERKS Malaysia to discuss some of the topics below:

-how better air pollution data is helping us all breathe easier
-how can smart systems improve the efficiency, resilience and performance of a building
-how the upgrade of Alila Bangsar Kuala Lumpur’s executive floor to Enviro Allergy Friendly rooms will be a game changer in the hospitality industry

The panel will comprise of:

1. Nitesh Malani, Group CEO ENVIROVERKS Malaysia
2. Dustin Jefferson Onghanseng, Co-Founder & CEO, uHoo
3. Kamal Munasinghe, General Manager, Alila Bangsar Kuala Lumpur
4. Matthias Gelber, Eco Warriors

Details of the launch are as below:

Day/Date: Tuesday 2 October 2018

Time: 2.00 pm

Venue: Level 9, Alila Bangsar Kuala Lumpur

You are cordially invited to send your reporter and photographer/cameraman to attend the event.

Source: XHale Asia (M) Sdn Bhd

FOR MORE INFORMATION, PLEASE CONTACT:
Name: Sumitra Valliappan
Tel: 012 444 5025
Email: sumitra.valliappan@gmail.com

Source: BERNAMA

The rising number of chronic diseases linked to poor indoor air quality has brought to light the urgency for a better understanding in addressing the problem.

uHoo co-founder and CEO Dustin Onghanseng said sick building syndrome (SBS) or building-related illness (BRI) has been a cause of concern for most building occupants who fall ill due to poor indoor air quality.

However, he said recent innovations in low-cost air pollution sensors have enabled a new generation of air quality monitoring devices that provide actionable high-resolution data at a fraction of the cost of traditional monitoring systems.

“Air quality used to be something that people rely on manual methods for information.

“However, the technology behind the Internet of Things has improved dramatically that sensors are now so small that you can monitor the quality of air you breathe in your homes or offices,” he said at the launch of the Enviro InteliAQ System in Kuala Lumpur yesterday.

According to Onghansen, a survey revealed that tenants were willing to pay 25% higher rent on better healthy building systems.

“Healthy buildings help shape the competitive price scale for the real estate market and may soon become the dealmaker or breaker in commercial property decisions.

“Also, 64% (of the tenants) in Asia Pacific are willing to pay extra for products and services produced or offered from companies that are committed to positive social and environmental impact,” he said.

Onghanseng added that companies could save up to RM30,000 on return on investment productivity per person per year by enhancing the wellbeing of occupants.

“Having good indoor air quality would lead to the increase of productivity and better decision-making. This is important because we spend more than 80% of our time indoors,” he said.

The Enviro InteliAQ System, which features nine air quality sensors packed into a tiny device about the size of a coffee mug, is first launched in Malaysia before being introduced in other regional markets.

The system, launched by Enviro Group Asia through its subsidiary Enviroverks (M) Sdn Bhd, also saw the group partnering boutique hotel Alila Bangsar.

Its group CEO Nitesh Malani said the collaboration will be a game-changer for the hospitality industry in the country as the company would help Alila Bangsar to ensure that its guests and staff are exposed to fewer pollutants and contaminations overall.

Enviro Group Asia has also entered into a collaborative distribution and research and development agreement with uHoo International, which will see the group expanding its regional footprint in the building sciences and environmental engineering sector.

Source: The Malaysian Reserve